Abstract
Purpose :
To evaluate post-treatment changes in the pupillary light response between the 0.01% and 0.025% atropine eye drops in myopic children.
Methods :
Study Design: Retrospective study.
Methods: We retrospectively analyzed myopic children who received 0.01% (0.01% group; N=60 eyes; mean age: 8.9 years; 66.7% boys) and 0.025% (0.025% group; N= 45 eyes; mean age: 8.8 years; 55.0% boys) atropine eye drop treatment at Toho University Omori Hospital. Pupil light response parameters were measured using an infrared pupillometer before and one month after treatment. Axial length was measured by IOL master. In both groups, changes in accommodative amplitude, distance, and near vision were compared before and one month after treatment. The degree of change in each parameter recorded using the pupil recorder was also compared between the two groups. Subjective symptoms were assessed using a questionnaire.
Results :
Both groups showed enlarged maximum and minimum pupil sizes, reduced pupil constriction, decreased latency time before the onset of pupil constriction, reduced rate of pupil constriction, and delayed time of 75% recovery at one-month post-treatment (p<0.001). However, both groups showed no significant post-treatment changes in accommodative amplitude, distance, or near vision. In addition, the 0.025% group showed significantly lower maximum pupil diameter (p<0.001), minimum pupil diameter (p<0.001), and pupil contraction rate (p<0.05) than the 0.01% group. There was no significant difference in the 6-month AL suppression effect between the two groups. Both groups had mild photophobia. There was no significant relationship between pupil metrics and the myopia progression during the treatment.
Conclusions :
Compared with the 0.01% group, the 0.025% group showed greater changes in pupil diameter enlargement and pupil constriction rate, but the frequency of photophobia and near vision impairment remained the same.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.